Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. decreased its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 39.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 32,306 shares of the biopharmaceutical company’s stock after selling 21,017 shares during the quarter. Russell Investments Group Ltd.’s holdings in Intra-Cellular Therapies were worth $2,698,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Intra-Cellular Therapies by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 9,721,360 shares of the biopharmaceutical company’s stock worth $811,928,000 after purchasing an additional 93,107 shares during the period. Norges Bank acquired a new position in shares of Intra-Cellular Therapies in the 4th quarter valued at about $268,347,000. Franklin Resources Inc. grew its position in shares of Intra-Cellular Therapies by 1.3% during the 4th quarter. Franklin Resources Inc. now owns 1,776,880 shares of the biopharmaceutical company’s stock valued at $148,405,000 after buying an additional 23,594 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Intra-Cellular Therapies by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,716,829 shares of the biopharmaceutical company’s stock worth $143,434,000 after acquiring an additional 8,528 shares during the last quarter. Finally, Wellington Management Group LLP boosted its stake in Intra-Cellular Therapies by 1.6% in the fourth quarter. Wellington Management Group LLP now owns 1,033,743 shares of the biopharmaceutical company’s stock valued at $86,338,000 after acquiring an additional 16,096 shares during the period. 92.33% of the stock is currently owned by institutional investors.

Intra-Cellular Therapies Stock Performance

ITCI stock opened at $131.87 on Friday. The firm’s 50-day moving average is $130.68 and its two-hundred day moving average is $105.56. The company has a market capitalization of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 52 week low of $64.09 and a 52 week high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The firm had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. On average, equities research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ITCI shares. Mizuho cut Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $140.00 to $132.00 in a research report on Monday, February 24th. Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and boosted their price target for the company from $119.00 to $132.00 in a report on Friday, January 31st. StockNews.com began coverage on shares of Intra-Cellular Therapies in a report on Sunday, April 13th. They issued a “hold” rating on the stock. Needham & Company LLC reissued a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $132.00 price target on shares of Intra-Cellular Therapies in a research note on Wednesday, April 2nd. Eleven analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $109.70.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.